Merck Sharp + Dohme Corp.

Isis Innovation Limited

Cambridge University Technical Services Limited

Tilos Therapeutics, Inc.

Other

Millennium Pharmaceuticals Limited

Synta Pharmaceuticals Corporation

Tolerx, Inc.

Tolerrx, Inc.

Cambridge Enterprise Limited

Patricia Rao

Herman Waldmann

Barbara S Fox

Mark Raymond Frewin

Jessie M English

Stavros Kopsiaftis

Scott Gorman

Geoff Hale

Tadeusz Kornaga

Douglas Ringler

Stephen Cobbold

Dawn Winsor-Hines

Randall Burton

Kenneth J Simon

Keizo Koya

Paul D Ponath

Yumiko Wada

Michael Rosenzweig

Jose F Ponte

Christopher Horvath

David Proia

Masazumi Nagai

L Mary Smith

Ronald K Blackman

Renee Moore

Xiufeng Song

A pharmaceutical composition comprising a PD-1 inhibitor and a Hsp90 inhibitor, or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4] triazole or 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate. Also provided is a method for treating cancer in a subject in need thereof, using the pharmaceutical composition described herein.

Combination therapy of HSP90 inhibitors and PD-1 inhibitors for treating cancer

Provided herein are antibodies which bind to latency-associated peptide (LAP) of TGF-&#x3b2;1 and are characterized by particular functional features, such as binding specifically to LAP-TGF&#x3b2;1 on cells but not to LAP-TGF&#x3b2;1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.

Methods of using anti-lap antibodies

Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF&#x3b2;1 on cells but not to LAP-TGF&#x3b2;1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.

Anti-lap antibody variants

The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof. Methods of using the binding molecules of the invention to detect human ILT3 or to modulate human ILT3 activity, either in vitro or in vivo, are also encompassed by the invention.

ILT3 binding molecules and uses therefor

Improved cancer treatments with bis[thiohydrazide amide] compounds such as elesclomol, in particular for identifying patient populations that would benefit from such treatments.

[object Object]

Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.

Compositions and methods of tolerizing a primate to an antigen

Anti-CD4 antibodies

The invention relates to a method of inhibiting stenosis or restenosis in a subject. In one embodiment, an agent which inhibits recruitment and/or adhesion of neutrophils and mononuclear cells to a site of vascular injury is administered to a subject in need thereof. In another embodiment, a first agent which inhibits recruitment and/or adhesion of neutrophils to a site of vascular injury, and a second agent which inhibits recruitment and/or adhesion of mononuclear cells to a site of vascular injury are administered to a subject in need thereof. In particular embodiments, the agents are antibodies or antigen-binding fragments thereof which bind to CD18 or CCR2.

Method of inhibiting stenosis and restenosis

Growing community of inventors

Acton, MA, United States of America

Patricia Rao